Two Sigma Securities’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$746K Buy
+314,693
New +$444K 0.06% 415
2025
Q3
– Sell
-32,017
Closed -$39.7K – 1855
2025
Q2
$39.7K Sell
32,017
-1,021
-3% -$1.18K ﹤0.01% 1130
2025
Q1
$39K Buy
+33,038
New +$50.7K 0.01% 1022
2023
Q2
– Sell
-11,995
Closed -$139K – 3194
2023
Q1
$139K Buy
+11,995
New +$119K ﹤0.01% 2152
2022
Q4
– Sell
-13,908
Closed -$81K – 3083
2022
Q3
$81K Sell
13,908
-8,859
-39% -$50.8K ﹤0.01% 2126
2022
Q2
$101K Buy
+22,767
New +$138K ﹤0.01% 1750
2019
Q3
– Sell
-16,622
Closed -$101K – 2342
2019
Q2
$101K Buy
+16,622
New +$117K ﹤0.01% 1848

Other funds holding PACB

Two Sigma Securities's PACB Position: Q3 2026 in Review

Two Sigma Securities opened a new position in Pacific Biosciences (PACB) in Q3 2026: 314,693 shares worth $746K. The stake represents 0.06% of the portfolio and ranks #415 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in PACB as recently as Q2 2025.

Two Sigma Securities first reported a position in PACB in Q2 2019 and has held it in 7 quarters since. 204 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Two Sigma Securities held 314,693 shares of Pacific Biosciences worth $746K as of Q3 2026.
  • Pacific Biosciences was a new Two Sigma Securities position in Q3 2026.
  • Pacific Biosciences made up 0.06% of Two Sigma Securities's portfolio in Q3 2026, its #415 holding.
  • Two Sigma Securities first reported a position in Pacific Biosciences in Q2 2019 and has held it in 7 quarters since.
  • 204 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Two Sigma Securities's 13F filing for Q3 2026, filed 16 Nov 2026.